ClinConnect ClinConnect Logo
Search / Trial NCT05877521

Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · May 17, 2023

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

Chronic Pain Cancer Pain Mindfulness Oriented Recovery Enhancement More Mindfulness Based Interventions Mb Is Memorial Sloan Kettering Cancer Center 23 082

ClinConnect Summary

This clinical trial is testing a program called Mindfulness-oriented Recovery Enhancement (MORE) to see if it can help relieve chronic pain in people with cancer. MORE is a type of therapy that uses mindfulness techniques, such as meditation, to help individuals focus on the present and accept their thoughts, feelings, and sensations. Researchers believe that this approach may help those suffering from ongoing pain related to their cancer.

To participate in the study, you need to be at least 18 years old, speak English, and have a history of cancer. You should also have chronic pain that has lasted for at least three months and be experiencing significant discomfort. If you qualify, you'll be randomly assigned to either the MORE program or a waiting list control group. The trial is currently recruiting participants, and you will have the opportunity to join virtual sessions from a private space. It’s important to note that individuals facing severe mental health challenges or planning certain medical procedures in the near future are not eligible to participate.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • English speaking
  • Age ≥ 18 years or older
  • A history of cancer with no restrictions placed on type of cancer
  • Determined to be either no-evidence of disease or stable oncological disease by referring or study physicians/advanced practice providers
  • Having a pain (musculoskeletal, generalized, or neuropathic) rating of 4 or greater in worst pain on a 0-10 numerical rating scale in the preceding week
  • Having had pain for at least 3 months and at least 15 days with pain in the preceding 30 days
  • Willing to adhere to all study-related procedures, including randomization to one of two treatment arms: MORE or WLC
  • Ability to attend video-call session and a quiet/private location
  • Exclusion Criteria:
  • Active suicidality or schizophrenia
  • Plan to initiate palliative radiation or interventional pain procedure within the next 12 weeks
  • Cognitive impairment preventing completing PRO independently or participate in virtual MORE as evaluated by study clinicians

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Jun Mao, MD, MSCE

Principal Investigator

Memorial Sloan Kettering Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported